<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988998</url>
  </required_header>
  <id_info>
    <org_study_id>FARTHER</org_study_id>
    <nct_id>NCT03988998</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma</brief_title>
  <official_title>radioFrequency Ablation With or Without RadioTherapy for Small HEpatocellulaR Carcinoma: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiofrequency ablation (RFA) and hepatic resection are main treatments for early stage
      hepatocellular carcinoma. Many randomized controlled trials found these two treatments have
      similar short term overall survival. However, hepatic resection is associated with higher
      long-term overall survival. These results reveal that tumor recurrence rate after RFA is
      higher than that after hepatic resection. And minimal residual tumor may exist after RFA.
      Radiotherapy after RFA may be effective to prevent early tumor recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Radiofrequency Ablation with or without Radiotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes (recurrence or death) Assessor is blind about the interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the 2-years recurrence rate</measure>
    <time_frame>2 year</time_frame>
    <description>Two year recurrence rate between the two groups will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the 2-years recurrence-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Two year recurrence-free survival between the two groups will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the 2-years overall survival.</measure>
    <time_frame>2 year</time_frame>
    <description>Two year overall survival between the two groups will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radiofrequency ablation with radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive liver radiotherapy around the primary tumor margin within one month after radiofrequency ablation for hepatocellular carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency ablation alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will only receive radiofrequency ablation for hepatocellular carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiofrequency ablation with radiotherapy</intervention_name>
    <description>Radiofrequency ablation with radiotherapy</description>
    <arm_group_label>Radiofrequency ablation with radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiofrequency ablation alone</intervention_name>
    <description>Radiofrequency ablation without radiotherapy</description>
    <arm_group_label>Radiofrequency ablation alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnoses of hepatocellular carcinoma based on EASL.

          2. Tumors, either single, &gt;2 and &lt; 5 cm in size or no more than 3 for size &lt; 3 cm.

          3. Patients must have a performance status of ECOG score &lt; 2.

          4. Patients must have adequate liver reservation and adequate hemogram.

               -  Pugh-Child's Score &lt; 7.

               -  The serum total bilirubin level are &lt; 2 mg/dl.

               -  The prothrombin times are &lt; 3 sec above normal control.

               -  The platelet are &gt; 75 x 109/L.

          5. Patient must have serum creatinine &lt; 1.5 mg/dl

          6. Cardiac function with NYHA classification &lt; Grade II

          7. HBsAg (+) .

          8. Signed informed consent.

        Exclusion Criteria:

          1. HCCs with radiological evidence of macrovascular invasion or extrehepatic metastasis
             are not eligible.

          2. Patients with other systemic diseases which required concurrent usage of
             glucoticosteroid or immunosuppressant agent(s) are not eligible.

          3. Patients with advanced second primary malignancy are not eligible.

          4. Patients with pregnancy or breast-feeding are not eligible.

          5. Patients with severe cardiopulmonary diseases are not eligible.

          6. Patients with clinically significant psychiatric disorder are not eligible.

          7. Patients who had antineoplastic chemotherapeutic or immuno-therapeutic drugs or
             corticosteroids within 6 weeks of commencing the protocol are not eligible.

          8. Patients who had prior antitumor therapy for HCC are not eligible.

          9. Anti-HCV positive patients are not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tang Wei-Zhong, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong Jian-Hong, PhD</last_name>
    <phone>0771-5301253</phone>
    <email>zhongjianhong@gxmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiang Bang-De, PhD</last_name>
    <phone>0771-5301253</phone>
    <email>xiangbangde@gxmu.edu.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2016 Feb 10;34(5):452-9. doi: 10.1200/JCO.2015.61.4925. Epub 2015 Nov 30.</citation>
    <PMID>26628466</PMID>
  </reference>
  <reference>
    <citation>Seo YS, Kim MS, Yoo HJ, Jang WI, Paik EK, Han CJ, Lee BH. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med. 2016 Nov;5(11):3094-3101. doi: 10.1002/cam4.893. Epub 2016 Oct 5. Review.</citation>
    <PMID>27709795</PMID>
  </reference>
  <reference>
    <citation>Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, Maeda S, Tanaka K, Numata K. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology. 2019 Jun;69(6):2533-2545. doi: 10.1002/hep.30591. Epub 2019 May 2.</citation>
    <PMID>30805950</PMID>
  </reference>
  <reference>
    <citation>Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, Seong J. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019 Feb;131:81-87. doi: 10.1016/j.radonc.2018.12.013. Epub 2018 Dec 31.</citation>
    <PMID>30773192</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Hong Zhong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

